BOSTON, Aug. 13, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that the CEO
Roundtable on Cancer named PAREXEL a CEO Cancer Gold
Standard™ employer. The accreditation recognizes
the Company's extraordinary commitment to the health of its
employees and their families.
"At PAREXEL, we have a passion for making a profound difference
in the lives of people – especially our employees and their
families," said Josef von
Rickenbach, Chairman and CEO, PAREXEL. "We are honored
the CEO Roundtable on Cancer named us a Gold Standard
employer, recognizing our commitment to the health and well-being
of our most important asset: our employees."
To earn CEO Cancer Gold Standard Accreditation, companies
must evaluate their health benefits and corporate culture and take
extensive, concrete actions to address cancer in the workplace.
PAREXEL established programs to reduce cancer risk, including:
- Prohibiting tobacco use and supporting tobacco cessation
efforts
- Promoting physical activity, healthy nutrition and weight
management
- Offering a Medical Incentive Program to reduce an employee's
health plan contribution following completion of health and
wellness activities
- Providing health insurance options that include detecting
cancer at its earliest stages, access to quality care and
participation in cancer clinical trials
- Supporting the needs of cancer survivors in the
workplace
Mr. Von Rickenbach added, "As an
expertise-based business, we work together every day towards our
goal of improving the lives of millions of patients. That
mission starts from within, by giving our employees the tools and
support to fight cancer."
About The CEO Roundtable on Cancer
The CEO
Roundtable on Cancer was founded in 2001, when former President
George H.W. Bush challenged a group
of executives to "do something bold and venturesome about cancer
within your own corporate families." The CEOs responded by creating
and encouraging the widespread adoption of the CEO Cancer Gold
Standard whichcalls for organizations to evaluate their health
benefits and workplace culture and take extensive, concrete actions
in five key areas of health and wellness to address cancer in the
workplace. For more information on the CEO Cancer Gold
Standard™ and the free web-based accreditation process and
support, please visit www.CancerGoldStandard.org.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL has offices in 80 locations in 51
countries around the world, and had approximately 18,660 employees
in the fourth quarter. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings, including expense
savings from the $30 – $45 million restructuring charge disclosed in the
press release dated June 23, 2015;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the acquisitions of ClinIntel Limited
and Quantum Solutions India, or enter into new lines of business;
the impact on the Company's business of government regulation of
the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of foreign
currency exchange rate fluctuations and other international
economic, political, and other risks. Such factors and others
are discussed more fully in the section entitled "Risk Factors" of
the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2015 as filed with the
Securities and Exchange Commission on May 1,
2015, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-receives-ceo-cancer-gold-standard-accreditation-300127824.html
SOURCE PAREXEL International Corporation